Minimal relapse risk and early normalization of survival for patients with Burkitt lymphoma treated with intensive immunochemotherapy: an international study of 264 real-world patients

Lasse H. Jakobsen, Fredrik Ellin, Knut B. Smeland, Tove Wästerlid, Jacob H. Christensen, Judit M. Jørgensen, Pär L. Josefsson, Andreas K. Øvlisen, Harald Holte, Yngvild N. Blaker, Jacob H. Grauslund, Jon Bjørn, Daniel Molin, Ingemar Lagerlöf, Karin E. Smedby, Katherine Colvin, Gita Thanarajasingam, Matthew J. Maurer, Thomas M. Habermann, Kevin W. SongKatie Y. Zhu, Alina S. Gerrie, Chan Y. Cheah, Tarec C. El-Galaly

Research output: Contribution to journalArticlepeer-review

3 Scopus citations

Fingerprint Dive into the research topics of 'Minimal relapse risk and early normalization of survival for patients with Burkitt lymphoma treated with intensive immunochemotherapy: an international study of 264 real-world patients'. Together they form a unique fingerprint.

Medicine & Life Sciences